NEURONAX will Present the Pre-Clinical Results of its Lead Product NX210 at Neuroscience 2017

(Lyon & Saint-Beauzire, France, November 9th, 2017) – NEURONAX, the biopharmaceutical company specializing in neuron protection and regeneration, will present its pre-clinical results highlighting the potential of its lead product NX210 at Neuroscience 2017. Organized by the Society for Neuroscience (SfN), Neuroscience 2017 is the world’s largest neuroscience conference for … Read more

NEURONAX at Neuro Advance Boston

Neuro Advance Boston is an off-the-record forum that brings together CMOs, CSOs, CEOs, and Heads of Neuro from top biopharmaceutical companies … Read more

NEURONAX supports IRME

In coherence with its vocation , Neuronax supports the Institute for Research on Spinal Cord and Encephalon (IRME). The mission of … Read more

NEURONAX at Bio-Europe 2016

NEURONAX is present in Biotechnology partnering Conference Bio-Europe in Cologne, 7-9 November 2016. NEURONAX’s CEO, Dr. Yann Godfrin and Founder … Read more